UY26779A1 - Prodrogas 3` de 2' -desoxi-b-l-nucleósidos - Google Patents
Prodrogas 3` de 2' -desoxi-b-l-nucleósidosInfo
- Publication number
- UY26779A1 UY26779A1 UY26779A UY26779A UY26779A1 UY 26779 A1 UY26779 A1 UY 26779A1 UY 26779 A UY26779 A UY 26779A UY 26779 A UY26779 A UY 26779A UY 26779 A1 UY26779 A1 UY 26779A1
- Authority
- UY
- Uruguay
- Prior art keywords
- deoxy
- nucleoside
- term
- prodrug
- refers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe un método para el tratamiento de la infección de hepatitis B en un huésped, incluyendo un humano, que incluye administrar una cantidad efectiva de una prodroga 3´de un 2´-desoxi-B-L nucleósidos activo desde el punto de vista biológico, o una sal del mismo aceptable para el farmacéutico, sola o en combinación, opcionalmente en un vehículo aceptable para el uso farmacéutico. Él termino 2´-desoxi, se refiere a un nucleósido que no tiene sustituyente en la posición 2´. Él termina prodroga 3´ se refiere a un 2´desoxi-B-L-nucleósido que tiene una porción separable en un ambiente biológico en la posición 3´ incluyendo, sin limitaciones, acilo y, en una realización, un L-aminoácido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21210000P | 2000-06-15 | 2000-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY26779A1 true UY26779A1 (es) | 2001-12-28 |
Family
ID=22789563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY26779A UY26779A1 (es) | 2000-06-15 | 2001-06-15 | Prodrogas 3` de 2' -desoxi-b-l-nucleósidos |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1296995B1 (es) |
| JP (1) | JP4639032B2 (es) |
| KR (2) | KR20070048277A (es) |
| CN (3) | CN1295242C (es) |
| AP (1) | AP1771A (es) |
| AR (1) | AR035711A1 (es) |
| AT (1) | ATE411332T1 (es) |
| AU (2) | AU6692701A (es) |
| BR (1) | BR0111732A (es) |
| CA (1) | CA2413163C (es) |
| CZ (1) | CZ2003122A3 (es) |
| DE (1) | DE60136181D1 (es) |
| EA (1) | EA005774B1 (es) |
| ES (1) | ES2317912T3 (es) |
| IL (3) | IL153379A0 (es) |
| MA (1) | MA27126A1 (es) |
| MX (1) | MXPA02012443A (es) |
| MY (1) | MY141594A (es) |
| NO (1) | NO20026001L (es) |
| NZ (2) | NZ523632A (es) |
| OA (1) | OA12384A (es) |
| PE (1) | PE20020216A1 (es) |
| PL (1) | PL360404A1 (es) |
| UY (1) | UY26779A1 (es) |
| WO (1) | WO2001096353A2 (es) |
| YU (1) | YU94802A (es) |
| ZA (2) | ZA200300168B (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2319732T3 (es) | 2000-04-13 | 2009-05-12 | Pharmasset, Inc. | Derivados de nucleosido 3'- o 2'-hidroximetilo sustituido para el tratamiento de infecciones virales. |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US6787526B1 (en) | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
| EP1736478B1 (en) | 2000-05-26 | 2015-07-22 | IDENIX Pharmaceuticals, Inc. | Methods and compositions for treating flaviviruses and pestiviruses |
| MXPA04012802A (es) | 2002-06-28 | 2005-04-19 | Idenix Cayman Ltd | Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae. |
| AU2003247084B9 (en) | 2002-06-28 | 2018-07-26 | Centre National De La Recherche Scientifique | Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| AU2003263412A1 (en) | 2002-06-28 | 2004-01-19 | Centre National De La Recherche Scientifique (Cnrs) | 1'-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections |
| BR0314259A (pt) | 2002-09-13 | 2005-07-26 | Idenix Cayman Ltd | ß-l-2'-desoxinucleosìdeos para o tratamento de cepas de hbv resistentes e terapias combinadas |
| MXPA05005192A (es) | 2002-11-15 | 2005-09-08 | Idenix Cayman Ltd | Nucleosidos ramificados en la posicion 2' y mutacion de flaviviridae. |
| KR20060008297A (ko) | 2003-03-20 | 2006-01-26 | 마이크로 바이올로지카 퀴미카 이 파마슈티카 리미티드 | 2'-데옥시-β-Ｌ-뉴클레오시드의 제조방법 |
| US7595390B2 (en) | 2003-04-28 | 2009-09-29 | Novartis Ag | Industrially scalable nucleoside synthesis |
| CN100503628C (zh) | 2003-05-30 | 2009-06-24 | 法莫赛特股份有限公司 | 修饰的氟化核苷类似物 |
| RU2361875C2 (ru) | 2003-06-30 | 2009-07-20 | Айденикс (Кайман) Лимитед | СИНТЕЗ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ |
| WO2005107742A1 (en) | 2004-05-05 | 2005-11-17 | Yale University | Novel antiviral helioxanthin analogs |
| KR101177590B1 (ko) | 2004-09-14 | 2012-08-27 | 파마셋 인코포레이티드 | 2'-플루오로-2'-알킬 치환되거나 또는 다른 선택적으로치환된 리보퓨라노실 피리미딘 및 퓨린 및 그 유도체의제조 |
| US7524831B2 (en) | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
| AR054778A1 (es) | 2005-06-17 | 2007-07-18 | Novartis Ag | Uso de sangliferina en hcv |
| GB0609178D0 (en) | 2006-05-09 | 2006-06-21 | Univ Cardiff | Novel compounds |
| US7897737B2 (en) | 2006-12-05 | 2011-03-01 | Lasergen, Inc. | 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| US8148503B2 (en) | 2008-06-11 | 2012-04-03 | Lasergen, Inc. | Nucleotides and nucleosides and methods for their use in DNA sequencing |
| US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
| TW201031675A (en) | 2008-12-23 | 2010-09-01 | Pharmasset Inc | Synthesis of purine nucleosides |
| AU2009329867B2 (en) | 2008-12-23 | 2015-01-29 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| HUE026235T2 (en) | 2010-03-31 | 2016-06-28 | Gilead Pharmasset Llc | Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -IL) - 4-Fluoro-3-hydroxy-4-methyltetrahydrofuran-2-IL) methoxy) (phenoxy) phosphoryl) amino) propanoate |
| CN102917585A (zh) | 2010-04-01 | 2013-02-06 | 埃迪尼克斯医药公司 | 用于治疗病毒感染的化合物和药物组合物 |
| TW201242974A (en) | 2010-11-30 | 2012-11-01 | Gilead Pharmasset Llc | Compounds |
| WO2012154321A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| EP2755985B1 (en) | 2011-09-12 | 2017-11-01 | Idenix Pharmaceuticals LLC | Compounds and pharmaceutical compositions for the treatment of viral infections |
| KR102048274B1 (ko) | 2011-09-13 | 2019-11-25 | 애질런트 테크놀로지스, 인크. | 핵산 시퀀싱을 위하여 5-메톡시, 3'-oh 차단안된, 신속하게 광절단가능한 종료 뉴클레오티드 및 핵산 시퀀싱 방법 |
| PL2709613T5 (pl) | 2011-09-16 | 2020-12-14 | Gilead Pharmasset Llc | Metody leczenia hcv |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| AR090699A1 (es) * | 2012-04-18 | 2014-12-03 | Biocryst Pharm Inc | Compuestos inhibidores de la actividad de la arn polimerasa viral |
| SG10201706949VA (en) | 2013-01-31 | 2017-09-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| MX2016002185A (es) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Formulacion combinada de dos compuestos antivirales. |
| IL277725B2 (en) * | 2018-04-12 | 2024-02-01 | Modis Therapeutics Inc | Pro-drugs of deoxynucleosides for the treatment of diseases resulting from an imbalance in the nucleotide reserves |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4958013A (en) * | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
| IT1246983B (it) * | 1990-11-13 | 1994-12-12 | Consiglio Nazionale Ricerche | L-2'-desossiuridine e composizioni farmaceutiche che le contengono. |
| US5559101A (en) * | 1994-10-24 | 1996-09-24 | Genencor International, Inc. | L-ribofuranosyl nucleosides |
| SE505648C2 (sv) * | 1996-08-30 | 1997-09-22 | Scania Cv Ab | Anordning vid ett fordon för monterbar anfästning av en förarplatsmodul |
| ES2255295T3 (es) * | 1998-08-10 | 2006-06-16 | Idenix (Cayman) Limited | 2'-deoxi-beta-l-nucleosidos para el tratamiento de la hepatitis b. |
-
2001
- 2001-06-14 MY MYPI20012807A patent/MY141594A/en unknown
- 2001-06-15 AT AT01944522T patent/ATE411332T1/de not_active IP Right Cessation
- 2001-06-15 JP JP2002510494A patent/JP4639032B2/ja not_active Expired - Lifetime
- 2001-06-15 EA EA200300023A patent/EA005774B1/ru not_active IP Right Cessation
- 2001-06-15 CN CNB018138020A patent/CN1295242C/zh not_active Expired - Fee Related
- 2001-06-15 CZ CZ2003122A patent/CZ2003122A3/cs unknown
- 2001-06-15 AP APAP/P/2003/002713A patent/AP1771A/en active
- 2001-06-15 UY UY26779A patent/UY26779A1/es not_active Application Discontinuation
- 2001-06-15 KR KR1020077009124A patent/KR20070048277A/ko not_active Application Discontinuation
- 2001-06-15 AU AU6692701A patent/AU6692701A/xx active Pending
- 2001-06-15 OA OA1200200374A patent/OA12384A/en unknown
- 2001-06-15 NZ NZ523632A patent/NZ523632A/en unknown
- 2001-06-15 CA CA002413163A patent/CA2413163C/en not_active Expired - Lifetime
- 2001-06-15 ES ES01944522T patent/ES2317912T3/es not_active Expired - Lifetime
- 2001-06-15 MX MXPA02012443A patent/MXPA02012443A/es active IP Right Grant
- 2001-06-15 WO PCT/US2001/019147 patent/WO2001096353A2/en active Application Filing
- 2001-06-15 PE PE2001000584A patent/PE20020216A1/es not_active Application Discontinuation
- 2001-06-15 AR ARP010102881A patent/AR035711A1/es not_active Application Discontinuation
- 2001-06-15 KR KR1020027017018A patent/KR20030032967A/ko active IP Right Grant
- 2001-06-15 IL IL15337901A patent/IL153379A0/xx active IP Right Grant
- 2001-06-15 BR BR0111732-7A patent/BR0111732A/pt not_active IP Right Cessation
- 2001-06-15 NZ NZ535246A patent/NZ535246A/en unknown
- 2001-06-15 CN CNA2006101495863A patent/CN101012259A/zh active Pending
- 2001-06-15 DE DE60136181T patent/DE60136181D1/de not_active Expired - Lifetime
- 2001-06-15 PL PL36040401A patent/PL360404A1/xx not_active Application Discontinuation
- 2001-06-15 EP EP01944522A patent/EP1296995B1/en not_active Expired - Lifetime
- 2001-06-15 CN CNA2006100741038A patent/CN1900104A/zh active Pending
- 2001-06-15 YU YU94802A patent/YU94802A/sh unknown
- 2001-06-15 AU AU2001266927A patent/AU2001266927B2/en not_active Ceased
-
2002
- 2002-12-11 IL IL153379A patent/IL153379A/en not_active IP Right Cessation
- 2002-12-13 NO NO20026001A patent/NO20026001L/no unknown
-
2003
- 2003-01-02 MA MA26989A patent/MA27126A1/fr unknown
- 2003-01-07 ZA ZA200300168A patent/ZA200300168B/en unknown
-
2004
- 2004-06-01 ZA ZA200404306A patent/ZA200404306B/xx unknown
-
2006
- 2006-10-25 IL IL178864A patent/IL178864A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY26779A1 (es) | Prodrogas 3` de 2' -desoxi-b-l-nucleósidos | |
| DE69521994D1 (de) | Zusammensetzungen welche dna zerstoerende agentien und p53 enthalten | |
| ATE131730T1 (de) | Nukleosidanalogen enthaltende antiviren- zubereitungen | |
| UY27875A1 (es) | Prodrogas 2 ' y 3 ' de nucleósidos modificados para tratar flaviviridae | |
| CU23367A3 (es) | Formulación de moxifloxacino con sal común | |
| BR0012082A (pt) | Formulação farmacêutica para administração compreendendo morfina e seu uso | |
| PT1256339E (pt) | Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina | |
| BRPI0413974A (pt) | combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação | |
| DE69521693T2 (de) | Taxanderivate enthaltende arzneizubereitungen | |
| MX9205922A (es) | Composiciones de sales de antibiotico lipofilico oligosacarido. | |
| AR019261A1 (es) | Cetoazalido de la clase de lactamas de 15 miembros, su uso, procedimiento para prepararlo , y una composicion farmaceutica util para el tratamiento de infecciones bacterianas en seres humanos y animales | |
| BR9916114A (pt) | Uso de apomorfina na fabricação de um medicamento para tratamento de disfunção erétil orgânica masculina | |
| ES2168241T1 (es) | Preparacion farmaceutica que contiene tolperisona para administrar por via oral. | |
| IT1314185B1 (it) | Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi | |
| ATE173627T1 (de) | Medizinische zusammensetzung | |
| AR022250A1 (es) | Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b. | |
| DK0593562T3 (da) | Topisk præparat indeholdende penciclovir | |
| ES2101311T3 (es) | Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer. | |
| ES2135476T3 (es) | Utilizacion de remacemida para el tratamiento de la enfermedad de parkinson. | |
| DE60322871D1 (de) | Thaltende zubereitungen | |
| AR007983A1 (es) | Formulacion | |
| Whitfield | HIV antiviral drug guide 1998 | |
| IL110888A0 (en) | Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative | |
| AR013424A1 (es) | Uso de uridina para la preparacion de una composicion farmaceutica util para inhibir la toxicidad de los analogos de pirimidina | |
| GT199800086A (es) | Formulaciones farmaceuticas que contienen voriconazol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20140509 |